ERAS Stock Analysis: Buy, Sell, or Hold?
ERAS - Erasca, Inc. Common Stock
$17.81
1.21 (7.29%)
▲
5d:
+17.48%
30d:
+17.79%
90d:
+378.76%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
ERAS is down 6.7% this week, but smart money is accumulating calls. Top strike: $15 2026-05-15 with 1 OI. Call ratio: 100% View Scanner →
Strength: 8.3/10
Get Alerted When ERAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ERAS is 12.2% above fair value ($15.87). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ERAS is 12.2% above fair value ($15.87). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ERAS is currently trading at $17.81, which is considered extended relative to its 30-day fair value range of $13.65 to $15.87.
Technical Outlook: Technically, ERAS is in a strong uptrend. The price is approaching resistance at $18.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: ERAS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ERAS is in a strong uptrend. The price is approaching resistance at $18.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: ERAS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$13.65 -
$15.87
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
ERAS is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+12.2% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.3%)
- BEARISH: Trading above Wall St target ($16.80)
Fair Price Analysis
30-Day Fair Range
$13.65 -
$15.87
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$13.86
Resistance Level
$18.18
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-32.89
Wall Street Target
$16.80
(-5.7%)
Share & Embed Analysis
Last updated: April 02, 2026 9:29 PM ET
Data refreshes hourly during market hours. Next update: 10:29 PM
Data refreshes hourly during market hours. Next update: 10:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Shannon Morris
SELL
20000 shares
2026-03-04
Ebun Garner
SELL
120000 shares
2026-01-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 60 HOLD |
Advanced ERAS Option Strategies
Professional options setups generated by AI based on today's ERAS price and gamma walls.
